These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


236 related items for PubMed ID: 34278433

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Determination of intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations in dried blood spots for pre-exposure prophylaxis adherence.
    Tsuchiya K, Hayashi Y, Ryu S, Tran HT, Takano M, Tanaka K, Mizushima D, Oka S, Gatanaga H, Hamada A.
    J Infect Chemother; 2024 Sep; 30(9):876-880. PubMed ID: 38431219
    [Abstract] [Full Text] [Related]

  • 25. Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study.
    Tapsoba JD, Cover J, Obong'o C, Brady M, Cressey TR, Mori K, Okomo G, Kariithi E, Obanda R, Oluoch-Madiang D, Chen YQ, Drain P, Duerr A.
    PLoS Med; 2022 Sep; 19(9):e1004097. PubMed ID: 36095005
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study.
    Odayar J, Orrell C, Phillips TK, Hu NC, Kabanda S, Malaba TR, Allerton J, Wiesner L, Hsiao NY, Castillo-Mancilla J, Lesosky M, Myer L.
    Clin Infect Dis; 2022 Sep 14; 75(5):761-767. PubMed ID: 34979553
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.
    Ojeda VD, Amico KR, Hughes JP, Wilson E, Li M, Holtz TH, Chitwarakorn A, Grant RM, Dye BJ, Bekker LG, Mannheimer S, Marzinke M, Hendrix CW.
    J Acquir Immune Defic Syndr; 2019 Sep 01; 82(1):34-40. PubMed ID: 31169769
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV.
    Peterson S, Ibrahim M, Anderson PL, Moore CM, MaWhinney S.
    J Pharmacokinet Pharmacodyn; 2021 Oct 01; 48(5):655-669. PubMed ID: 34013454
    [Abstract] [Full Text] [Related]

  • 34. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
    Pyra M, Anderson PL, Hendrix CW, Heffron R, Mugwanya K, Haberer JE, Thomas KK, Celum C, Donnell D, Marzinke MA, Bukusi EA, Mugo NR, Asiimwe S, Katabira E, Baeten JM, Partners Demonstration Study Team.
    AIDS; 2018 Aug 24; 32(13):1891-1898. PubMed ID: 29894385
    [Abstract] [Full Text] [Related]

  • 35. Feasibility, Acceptability, and Adherence with Short-Term HIV Preexposure Prophylaxis in Female Sexual Partners of Migrant Miners in Mozambique.
    Lahuerta M, Zerbe A, Baggaley R, Falcao J, Ahoua L, DiMattei P, Morales F, Ramiro I, El-Sadr WM.
    J Acquir Immune Defic Syndr; 2017 Dec 01; 76(4):343-347. PubMed ID: 28777264
    [Abstract] [Full Text] [Related]

  • 36. A pilot program of HIV pre-exposure prophylaxis in Thai youth.
    Rungmaitree S, Werarak P, Pumpradit W, Phongsamart W, Lapphra K, Wittawatmongkol O, Durier Y, Maleesatharn A, Kuttiparambil B, Cressey TR, Hoffman RM, Chokephaibulkit K.
    PLoS One; 2024 Dec 01; 19(2):e0298914. PubMed ID: 38386680
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring.
    Niu X, Kubiak RW, Siriprakaisil O, Klinbuyaem V, Sukrakanchana PO, Cressey R, Okochi H, Gandhi M, Cressey TR, Drain PK.
    Open Forum Infect Dis; 2022 Aug 01; 9(8):ofac405. PubMed ID: 36004315
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 12.